OnCore Login

Return to Trial Database

HCRN-LUN02-50

A Phase II Trial of Gefitinib (Iressa®) Plus Celecoxib (Celebrex®) in Chemotherapy-naïve Patients with Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC)

Status

Study Completed

Cancer Type(s)

Lung

Study Contact

Publications

Gefitinib plus Celecoxib in Chemotherapy-Naïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC): A Phase II Study
  • A Agarwala, L Einhorn, W Fisher, D Bruetman, J McClean, D Taber, M Titzer, B Juliar, T Breen, N Hanna
Gefitinib plus Celecoxib in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer: a phase II study
  • A Agarwala, W Fisher, D Bruetman, J McClean, D Taber, M Titzer, B Juliar, M Yu, T Breen, L Einhorn, N Hanna
Gefitinib in Patients with Chemo-sensitive and Chemo-refractory Relapsed Small Cell Cancers: A Phase II Trial
  • AM Moore, LH Einhorn, D Estes, R Govindan, J Axelson, J Vinson, TE Breen, M Yu, NH Hanna

Trial Locations

All sites in which the trial HCRN-LUN02-50 being conducted in.
No data was found
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278